financetom
Business
financetom
/
Business
/
What's Going On With Plug Power Stock Friday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Plug Power Stock Friday?
Nov 21, 2025 11:38 AM

Plug Power, Inc. ( PLUG ) stock rose Friday after closing a major refinancing that reshaped its balance sheet.

The company also scheduled a key shareholder vote to expand its authorized share count next year.

Plug closed a convertible note offering totaling $431.25 million due in 2033.

Also Read: BJ’s Wholesale Shines As Shoppers Go Premium And Stay Loyal

The deal included full exercise of the underwriters’ additional purchase option. After fees and expenses, Plug received about $399.4 million in net proceeds.

The company will use the proceeds to retire the remaining high-cost 15% debt.

It will also refinance 2026 convertible notes. Management eliminated a restrictive first lien from its former lender.

Capital Structure Shift

Plug now benefits from an eight-year balloon structure with no required amortization. This extends its lower-cost capital through 2033. The structure removes near-term principal repayment pressure.

Management said the changes lower interest expense and simplify financing layers. The company now considers its operating plan fully funded under current assumptions. Recent data center infrastructure agreements support this funding outlook.

Andy Marsh, CEO of Plug Power ( PLUG ), said: “This financing marks a major turning point for Plug.” He added that the stronger balance sheet improves flexibility as demand for hydrogen technologies rises.

Operational Positioning

Plug already holds sufficient manufacturing capacity for its projected growth.

The company aims to expand across material handling fleets and utility-scale electrolyzer deployments. Management believes demand momentum continues building across sectors.

Upcoming Shareholder Vote

Plug will hold a special shareholder meeting on Jan. 15, 2026, in a virtual format. Stockholders will vote on increasing authorized common shares from 1.5 billion to 3 billion.

The proposal also includes updates aligning Plug’s charter with recent Delaware law revisions. These changes reduce voting hurdles for future share authorization adjustments.

Price Action: PLUG shares were trading higher by 1.32% to $1.915 at last check Friday.

Read Next:

Target Struggles As Consumers Skip Non-Essential Buys

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
BRIEF-Strathcona Resources Announces Amended And Extended Offer To Acquire Meg Energy Corp
Sep 8, 2025
Sept 8 (Reuters) - STRATHCONA RESOURCES ( STHRF ): * STRATHCONA RESOURCES ( STHRF ) - MEG BOARD DEAL IS UNFAIR TO MEG SHAREHOLDERS AND RESULT OF A BROKEN SALE PROCESS * STRATHCONA RESOURCES LTD. ( STHRF ) ANNOUNCES AMENDED AND EXTENDED OFFER TO ACQUIRE MEG ENERGY CORP. * STRATHCONA RESOURCES LTD ( STHRF ) - AMENDED OFFER EQUATES TO...
Chevron seeks diversified approach to refinery investment
Chevron seeks diversified approach to refinery investment
Sep 8, 2025
SINGAPORE, Sept 8 (Reuters) - Chevron ( CVX ) is looking to have a balanced portfolio of refineries, Brant Fish, the U.S. major's president, international products, said at the APPEC event in Singapore. There'll be places like Korea where we go investment heavy in petrochemicals and in heavy oil upgrading, Fish said of the firm's existing investments. And then there'll...
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
AstraZeneca Says Tagrisso Combination Therapy Demonstrates Superior Overall Survival in Late-Stage Trial
Sep 8, 2025
04:27 AM EDT, 09/08/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Sunday that results from a phase 3 trial of Tagrisso plus pemetrexed and platinum-based chemotherapy showed statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival compared with Tagrisso alone in patients with non-small cell lung cancer. The Tagrisso combination therapy showed a median...
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Sep 8, 2025
04:03 AM EDT, 09/08/2025 (MT Newswires) -- Alkermes ( ALKS ) said Sunday that a phase 2 study of its investigational drug alixorexton in patients with type 1 narcolepsy showed clinically meaningful and statistically significant improvements in wakefulness, cognition and fatigue that were sustained over a six-week treatment period. The 92-patient study met its primary endpoint of improvements in mean...
Copyright 2023-2025 - www.financetom.com All Rights Reserved